结直肠癌原发灶与脑转移瘤的分子遗传学一致性比较 (GENCONCOR-1)
GENCONCOR-1 study is translational research aimed to investigate the concordance of the molecular genetic profile of the primary tumor and brain metastases (BM) of colorectal cancer (CRC). The study was conducted by post hoc analysis of pairs of samples of histological material with determination of the mutational status of genes KRAS, NRAS, BRAF, HER2 and MSI.
研究概览
地位
详细说明
Brain metastases (BM) from colorectal cancer (CRC) are a rare event reported in less than 3% of patients with CRC (the reported incidence ranges from 0.27 to 3%). This course is associated with a poor prognosis. Treatment of these patients remains challenging. Nevertheless, given the rarity of the event, at this time not enough is known about molecular biology of BM from colorectal cancer and its concordance with matched primary tumors.
In N.N. Blokhin National Medical Research Center of Oncology over 26 years (1998-2024) identified 108 patients with BM from CRC. Of this number, 72 patients had a history of neurosurgical resection of BM. In turn, for 32 patients access to a pair of tumor samples: from the primary tumor and from intracranial metastases. Tumor samples will be tested for mutation status of genes KRAS, NRAS, BRAF, HER2 and MSI. Analysis was limited to this pool of genes because of their clinical relevance and potential prognostic information. The molecular profile of the BM will be compared with the corresponding primary tumor with calculation of concordance rate (%).
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:David Halafyan, MD
- 电话号码:+7(930)928-00-72
- 邮箱:daveupnow@gmail.com
学习地点
-
-
Moscow
-
Moscow、Moscow、俄罗斯、115478
- 招聘中
- Blokhin's Russian Cancer Research Center
-
接触:
- David Halafyan, MD
- 电话号码:+7(930)928-00-72
- 邮箱:daveupnow@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with metastatic colorectal cancer (CRC) and brain metastases (BM) will be analyzed according to sex, age, functional status (ECOG 0-1 or 2-3), number of BM (solitary or ≥ 2), clinical manifestations of BM (symptomatic or asymptomatic), extracranial lesions at the time of diagnosis BM (present or absent), course of brain metastases (synchronous with the primary tumor or metachronous), side of the location of the primary tumor (left-sided or right-sided CRC), location of intracranial lesions (supratentorial or subtentorial), number of previous lines of drug therapy.
描述
Inclusion Criteria:
- Men and women over 18 years of age.
- Histologically confirmed cancer of the colon or rectum.
- Histologically confirmed metastatic lesion of the brain.
- Neurosurgical resection for brain metastases of colorectal cancer.
- Presence of paired tumor samples (both primary tumor and intracranial material).
Exclusion Criteria:
- Missing one sample from a pair of tumor samples.
- Low quality or lack of tumor material for molecular genetic research.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:RETROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Concordance rate (%)
大体时间:1 month
|
Concordance rate (%) between mutational status of the brain lesions and their corresponding primary tumor. Calculated as the ratio of concordant cases to total cases. |
1 month
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Intracranial progression-free survival (CNS-PFS1)
大体时间:3 months
|
Time from the date of cancer diagnosis to the date of detection of brain metastases. |
3 months
|
|
Overall survival (OS)
大体时间:6 months
|
Time from the date of detection of brain metastases to the date of death. |
6 months
|
|
Intracranial progression-free survival (CNS-PFS2)
大体时间:3 months
|
Time from the date of neurosurgical resection to the date of intracranial progression (continued growth or distant brain metastases) or death. |
3 months
|
合作者和调查者
调查人员
- 学习椅:Alexey Tryakin, MD, professor、Blokhin's Russian Cancer Research Center
- 学习椅:Ali Bekyashev, MD, professor、Blokhin's Russian Cancer Research Center
- 学习椅:Anna Stroganova, MD、Blokhin's Russian Cancer Research Center
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 115522143966
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data that underline the results reported in article, after deidentification (text, tables, figures, and appendices)
IPD 共享时间框架
From the moment of publication of the results and indefinitely
IPD 共享访问标准
For individual participant data meta-analysis. Data will be available indefinitely in the appendix of the published article
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.